Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
Investigative Site, Anaheim, California University of Maryland, Institute of Human Virology, Clinical Research Unit, Baltimore, Maryland The New York-Presbyterian Hospital, New York, New York Moldova
IMSP Spitalul Clinic de Boli Infectioase "Toma Ciorba", Chinsinau PMSI Clinical Republican Hospital "Timofei Mosneaga", Chisinau Romania
Infectious Diseases Institutul National De Boli Infectioase Prof. Matei Bals, Bucharest South Korea
Korea University Ansan Hospital, Ansan-si The Catholic University of Korea Bucheon St. Mary's Hospital, Bucheon-si The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul Samsung Medical Center, Seoul Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City